翰宇药业(300199.SZ)拟终止对“全资香港子公司”项目中溴麦角环肽项目的投资
格隆汇12月31日丨翰宇药业(300199.SZ)公布,公司2019年12月31日召开第四届董事会第十二次会议和第四届监事会第九次会议,审议通过《关于变更部分超募资金投资项目暨部分项目结项的议案》,根据公司发展战略及募集资金投资项目实施情况,为提高公司募集资金使用效率,按照相关法律法规和《公司募集资金管理制度》的有关规定,同意公司对超募资金投资项目“设立香港全资子公司”的具体实施进行调整以及部分项目结项的事项。
经审慎考虑,公司拟终止对“全资香港子公司”项目中溴麦角环肽项目的投资,继续推进多肽制剂、原料药海外注册和销售项目,以及客户肽等产品海外销售项目和香港翰宇的持续运营。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.